What You Should Know:
- Revalia Bio Inc., a new pre-clinical research company secures $14.5M in seed funding round to support the launch of its "Human Data Trials".
- The funding was co-led by America's Frontier Fund and Sierra Ventures, with participation from Roger Ferguson, former Vice Chair of the U.S. Federal Reserve, and other existing investors. This brings Revalia's total funding to $19.5M.
A New Paradigm for Pre-Clinical Research
The investment comes at a crucial time
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Ketryx Raises $39M to Accelerate AI-Powered Compliance in Life Sciences
What You Should Know:
- Ketryx, the AI-powered compliance platform helping life sciences companies ship safer products faster, today announced a $39 million Series B led by Transformation Capital, with participation from existing investors including Lightspeed Venture Partners, MIT’s E14 Fund, Ubiquity Ventures, and 53 Stations.
- This latest round brings the company’s total funding to over $55 million, and Vinay Shah, Partner and Founding Team Member at Transformation
Read More
ArcaScience Raises $7M to Advance AI-Powered Drug Benefit-Risk Evaluation
What You Should Know:
- ArcaScience, a Paris, France-based AI Healthtech startup, has announced a $7M seed funding round led by The Moon Venture, with participation from Pléiade Venture, Plug&Play Ventures, Bpifrance, and AKKA Technologies. This marks the company's first institutional funding round, following a €1.3 million pre-seed raise.
- The new funds will be used to expand operations in the U.S. and U.K., launch the company’s first patient-facing solution, and strategically
Read More
Medable Launches Agent Studio, the First Agentic AI Platform for Life Sciences
What You Should Know:
- Medable, a technology provider for clinical development, has launched Agent Studio, which it calls the industry's first agentic AI platform purpose-built for life sciences.
- Agent Studio is a no-code agent-builder that allows clinical teams to quickly custom-configure AI agents. Medable also introduced CRA Agent, a pre-built agent designed for clinical trial monitoring that runs on the Agent Studio platform. Both Agent Studio and CRA Agent are intended
Read More
Alphabet’s Verily Shuts Down Medical Device Division, Shifts Focus to AI
What You Should Know:
- Alphabet's Verily announced in an internal memo that is has closed its medical device division and laid off staff. The exact number of employees affected was not revealed.
- According to a spokesperson, the company has made the "difficult decision to discontinue manufacturing medical devices" and will no longer support them moving forward. This move is a continuation of a broader strategic shift from Alphabet in 2023, which saw the company cut 12,000 positions
Read More
Veeva Systems and Amgen Partner to Advance Clinical Trial Innovation
What You Should Know:
- Veeva Systems has announced a new collaboration with Amgen, a global leader in biotechnology, to advance clinical trial innovation.
- Amgen will use the Veeva Clinical Platform to find and implement efficiencies across its clinical trial processes.
Connected Platform for Clinical Development
The Veeva Clinical Platform is a complete and connected platform that covers clinical operations and data applications. This end-to-end platform includes
Read More
Cleveland Clinic and Dyania Health Partner to Accelerate Clinical Trial Recruitment with AI
What You Should Know:
- Cleveland Clinic and Dyania Health have announced a collaboration to integrate Dyania's Synapsis™ AI platform across Cleveland Clinic’s clinical research enterprise.
- The partnership, which follows successful pilot programs in cardiology, oncology, and neurology, aims to accelerate clinical trial recruitment by using medically trained large language models (LLMs) to speed up and scale patient identification for research studies. The ultimate goal is to provide more
Read More
EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization
What You Should Know:
- EVERSANA and Waltz Health have announced a merger valued at $6B to form a unified healthcare platform that will redefine pharmaceutical commercialization and patient access.
- The merger combines Waltz Health’s software-powered drug-price marketplaces and direct-to-payer model with EVERSANA’s global commercialization services. The new organization aims to deliver a next-generation approach to drug access and value in the U.S. healthcare system, particularly
Read More
Eli Lilly’s Oral GLP-1 Orforglipron Successful in Third Phase 3 Trial
What You Should Know:
- Eli Lilly and Company has announced positive topline results from its Phase 3 ATTAIN-2 trial, which evaluated orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes.
- All three doses of the drug met the primary and all key secondary endpoints, showing significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors over 72 weeks.
Significant Weight Loss and
Read More
AbbVie Acquires Gilgamesh’s Psychedelic MDD Program For Up To $1.2B
What You Should Know:
- AbbVie and Gilgamesh Pharmaceuticals Inc. have announced a definitive agreement for AbbVie to acquire Gilgamesh's lead investigational candidate, bretisilocin, which is in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
- The deal is valued at up to $1.2B, which includes an upfront payment and development milestones. As part of the acquisition, Gilgamesh will spin off a new entity that will
Read More
